Media Center

Media Center

Sandoz TV Episode 18: Trailer

Find out what to expect from the newest episode of Sandoz TV.

Global News Sandoz Around the World Sandoz in the Media

Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept

Holzkirchen, December 08, 2015

Sandoz is seeking approval for all indications included in the reference product’s label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis.

Phase III data shows Sandoz’ proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product

Holzkirchen, December 07, 2015

PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer.


Holzkirchen, November 20, 2015

On November 19, Richard Francis, Global Head of Sandoz, a Novartis Company presented two key regional policy recommendations at this year’s International Consultative Conference for Economic Development (ICCFED) in Guangzhou, China.

Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in the UK

Holzkirchen, November 20, 2015

Sandoz, a Novartis company, today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in the United Kingdom.

Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by the FDA

Holzkirchen, November 18, 2015

Sandoz demonstrates commitment to oncology by seeking approval for its proposed biosimilar pegfilgrastim.

More News